𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer

✍ Scribed by O'Brien, MER; Nicolson, M; Montes, A; Tidy, A; Ashley, S; Powles, TJ

Book ID
109837052
Publisher
Nature Publishing Group
Year
1994
Tongue
English
Weight
706 KB
Volume
70
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I trial of paclitaxel, carboplatin
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

Phase I/II study of carboplatin and oral
Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer
✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-